另外，食品的加工过程 - 清洗、整理、去除下脚料、烫漂、蒸煮、油炸等手段都可导致矿物质和维生素大量损失。食品在烫漂或蒸煮时，与水接触沥滤后，造成矿物质和维生素流失；烹调时，矿物质易从汤汁内流失，而维生素遇热分解。如豆子煮熟后矿物质的损失非常显著，西红柿加热后维生素C 损失严重；谷物是矿物质的一个重要来源。谷物的胚芽和糊粉层中富含矿物质，而谷物在碾磨时会损失大量的矿物质，损失量随碾磨的精度而增加。人类的饮食正在由原始的粗粮向细粮转化，或者基本已经完成了转化。食品中矿物质损失的另一途径是与食品中其他成分的相互作用而导致生物利用率的下降。一些多价阴离子，如广泛存在于植物性食物中的草酸、植酸等能与二价金属离子如铁、钙等形成相应的盐，而这些盐是非常不易溶解的，在消化道中被机体吸收利用的程度很低，造成矿物质营养质量下降。
Oxidativer Stress und Altern
Kuklinski B, Pietschmann A .Z Geriatrie 1991 224-246
Review: Oxidative stress and the aging process. A description of the involvement of oxidative stress during aging. Antioxidants and their specific effects are presented. Epidemiological investigations in Germany revealed an undersupply with nutritional anti- oxidants. The higest deficit could be found in selenium, an essential trace element for radical scavenger enzymes. This may lead to a deficiency in vitamin E. Oxidative stress activates the cascade of arachidon acid, as well as inducing inflow of intracellular calcium. These changes on a subcellular level, contribute to immunodis- turbances and enhancement of cancer- and atherogenesis.
Kliniska effekter kost supplementering med ubiquinon, coensym Q10
Nylander M. Biomed 1991 6-11
Six people with varying degree of parodontosis were given a daily oral supplement of 30-100 mg of ubiquinone (Bio-Qinon, Pharma Nord) for 6-12 weeks. The results indicate that ubiquinone can attenuate the degree of bleeding tendency and/or inflammation of the gingvia in individuals showing parodontosis. Time needed of supplementation for therapeutic effect varied individually.
Coenzyme Q10 protects ischemic myocardium in an open-chestswine model
Atar D, Philips C, Scott H, Mortensen SA, et al.
7th int. conference on the biomed. and clin. aspec 1992
Coenzyme Q10 Protects Ischemic Myocardium in an Open-Chest Swine Model.
Atar D, Mortensen SA, Flachs H, Herzog WR. Clin Investig 1993 71 S103-11
Myocardial stunning, defined as a reversible decrease in contractility after ischemia and reperfusion, may be a manifestation of reperfusion injury caused by free oxygen radical damage. The aim of this study was to test the hypothesis that pretreatment with coenzyme Q10, believed to act as a free radical scavenger, reduces myocardial stunning in a porcine model. 12 swine were randomized to receive either oral supplementation with Q10 (200 mg twice daily as soft capsules) or placebo for 20 days. A normothermic open- chest model was used with short occlusion (8 min) of the distal left descending coronary artery (LAD) followed by reperfusion. Regional contractile function was measured with epicardial Doppler crystals in ischemic and non-ischemic segments by measuring thickening fraction of the left ventricular wall during systole. Stunning time was defined as the elapsed time of reduced contractility until return to baseline. Concentrations of reduced CoQ10 were measured in blood and homogenized myocardial tissue, using high- performance liquid chromatography (HPLC). Plasma levels of reduced coenzyme Q10 (ubiquinol) were higher in swine pretreated with the experimental medication as compared to placebo (mean 0.45 mg/l versus 0.11 mg/l, respectively). Myocardial tissue concentrations, however, did not show any changes (mean 0.79).
Perspectives on Therapy of Cardiovascular Diseases with CoQ10.
Mortensen SA. Clin Investig 1993 71 S116-23
A defective myocardial energy supply - due to lack of substrates and/or essential cofactors and a poor utilization efficiency of oxygen - may be a common final pathway in the progression of myocardial diseases of various etiologies. The vitamin-like, essential substance Coenzyme Q10 (CoQ10) has a key role in the oxidative phosphorylation. A biochemical rationale for using CoQ10 as a therapy in heart disease was been established years ago by Folkers and associates; however, this has been further strengthened by investigations of viable myocardial tissue from the author's series of 45 patients with various cardiomyopathies. Myocardial tissue levels of CoQ10 determined by HPLC were found significantly lower in groups with more advanced heart failure (NYHA classes III and IV) compared with those patients in the milder stages of heart failure. Furthermore, the tissue CoQ10 deficiency was significantly restored by oral therapy, 100 mg CoQ10 daily (dissolved in soy-bean oil and administered in soft gelatine capsules). In a series of 40 patients with heart failure of various origin at Rigshospitalet nearly two thirds revealed clinical improvement, most pronounced in patients with dilated cardiomyopathy. Double-blind placebo-controlled trials have definitely confirmed that coenzyme Q10 has a place as adjunctive treatment in heart failure with beneficial effects on the clinical outcome, the patients' physical activity, and their quality of life. The positive results have been above and beyond the clinical status obtained from treatment with traditional principles - including angiotensin-converting enzyme inhibitors.
Selenium therapy in myocardial infarction.
Selentherapie des Herzinfarktes
Weisenbacher E, Kuklinski B, Erdmann D, Junghans P, et al.
1st Rostock symposium on antioxidants in medicine 1992
Partial and complete regression of breast cancer in patients in relation to dosage of coenzyme Q10
Lockwood K, Moesgaard S, Folkers K.
Biochem Biophys Res Commun 1994 199 1504-8
Relationships of nutrition and vitamin to the genesis and prevention of cancer are increasingly evident. In a clinical protocol, 32 patients having -"high-risk" breast cancer were treated with antioxidants, fatty acids, and 90 mg of CoQ10. Six of the 32 patients showed partial tumor regression. In one of these 6 cases, the dosage of CoQ10 was increased to 390 mg. In one month, the tumor was no longer palpable and in another month, mammography confirmed the absence of the tumor. Encouraged, another case having verified breast tumor, after nonradical surgery and with verified residual tumor in the tumor bed was treated with 300 mg CoQ10. After 3 months, this patient was in excellent clinical condition and there was no residual tumor tissue. The bioenergetic activity of CoQ10, expressed as hematological or immunological activity, may be the dominant but not the sole molecular mechanism causing the regression of breast cancer.
Coenzyme Q10 and antioxidants in acute myocardial infarction
Kuklinski B, Weissenbacher E, von Appen S.
8th. Int. Symp. Biomed. and Clin. Aspects of CoQ10 1993 32
Bioavailability of four oral coenzyme Q10 formulations in healthy volunteers 4种口服辅酶Q10制剂在健康志愿者中的生物利用率
Weis M, Mortensen SA, Rassing MR, et al.
8th. Int. Symp. Biomed. and Clin. Aspects of CoQ 1993 52
Symposium abstract - see A-2413
Bio-Qinon Q10: Bioavailability
Folkers K, Morita M.
8th. Int. Symp. Biomed. and Clin. Aspects of CoQ 1993 61
Effect of coenzyme Q10 supplementation on platelet agreegability in swine
Herzog WR, Atar D, Mortensen SA, Schlossberg, et al.
8th. Int. Symp. Biomed. and Clin. Aspects of CoQ 1993 62
A study on the anti-oxidative effects of coenzyme Q10 in humans
Weber C, Jacobsen TS, Mortensen SA.
8th. Int. Symp. Biomed. and Clin. Aspects of CoQ 1993 66
Coenzyme Q10 and diabetes mellitus: A 72-year-old man takingCoQ10 on his own accord could quit insulin injections
8th. Int. Symp. Biomed. and Clin. Aspects of CoQ10 1993 69
Apparent partial remission of breast cancer in "high risk"patients supplemented with nutr. antioxidants, EFA & CoQ10
Lockwood K, Moesgaard S, Hanioka T, Folkers K.
8th. Int. Symp. Biomed. and Clin. Aspects og CoQ. 1993 49
Abstract from the 8th International Symposium on Biomedical and Clinical Aspects of Coenzyme Q, Stockholm, Sweden, 1993.
Antioxidative effect of dietary coenzyme Q10 in human blood plasma
Weber C, Sejersg, Mortensen SA, Paulsen G, et al.
Internat J Vit Nutr Res 1994 64 311-315
The effect of an oral dose of 90 mg/day coenzyme Q10 on the antioxidative status in 22 healthy young subjects (9 men and 13 women) was investigated before and after induction of an oxidative stress by fish oil supplementation. The levels of oxidised and reduced coenzyme Q10, alpha tocopherol, ascorbate, TBARS and the fatty acid composition of phospholipids were determined in plasma. The total amount of plasma coenzyme Q10 increased significantly from 0.7 +/- 0.1 micromol/l before supplementation to 1.7 +/ 0.3 micromol/l after one week of supplementation while the redox status (reduced CoQ10/total CoQ10) remained constant, even during a following fish oil supplementation. The level of TBARS decreased during the first 2 weeks of CoQ10 ingestion while the content of alpha tocopherol increased in the second week and ascorbate did not change. The decrease of TBARS and the presence of the majority of the orally supplemented CoQ10 in the reduced form in plasma seem to indicate an antioxidative role of CoQ10 in blood plasma. ADDITIONAL AUTHORS : H
Weissenbacher E, Kuklinski B, Erdmann A, et al.
Selentherapie des herzinfarktes
1. Dresdner Selen-symposium 1992 20
ADDITIONAL AUTHORS : Junghans P Naumann G
Dose dependent effects of coenzyme Q10 on platelet aggregability in swine
Herzog WR, Mortensen SA, Schlossberg ML, Serebruany VL.
XV European Sec. Meeting, Copenhagen 1994 1994 623-626
Effect of Dietary Coenzyme Q10 as an Antioxidant in Human Plasma
Weber C, Jakobsen TS, Mortensen SA, Paulsen G, et al.
Mol Aspects Med 1994 15s s97-s102
A human study including 22 volunteers was conducted to investigate the antioxidative effect in blood of dietary Coenzyme Q10 supplementation (Bio-Qinon, Pharma Nord, Denmark). The levels of
Coenzyme Q10 and Antioxidants in Acute Myocardial Infarction
Kuklinski B, Weissenbacher E. Mol Aspects Med 1994 15s s143-s147
Sixty-one patients admitted with acute myocardial infarction, and a symptom's duration of less than 6 hr were randomized into two groups. Immediately after hospitalization, members of the verum group (n=32) received 500
Apparent Partial Remission of Breast Cancer in 'High Risk'Patients Supplemented with Nutr. Antioxidants, EFA & CoQ10
Lockwood K, Moesgaard S, Hanioka T, Folkers K.
Mol Aspects Med 1994 15s s231-s240
Thirty-two typical patients with breast cancer, aged 32-81 years and classified 'high risk' because if tumor spread to the lymph nodes in the axilla, were studied for 18 months following an Adjuvant Nutritional Intervention in Cancer protocol (ANICA protocol). The nutritional protocol was added to the surgical and therapeutic treatment of breast cancer, as required by regulations in Denmark. The added treatment was a combination of nutritional antioxidants (Vitamin C: 2850 mg, Vitamin E: 2500 iu,
Bioavailability of Four Oral Coenzyme Q10 Formulations inHealthy Volunteers
Weis M, Mortensen SA, Rassing MR, et al.
Mol Aspects Med 1994 15s s273-s280
The bioavailability of four different Coenzyme Q10 (CoQ) formulations was compared in ten healthy volunteers in a four-way randomised cross-over trial. The included formulations were: A hard gelatine capsule containing 100 mg of CoQ with 400 mg of Emcompress(R). Three soft gelatine capsules containing: 100 mg of CoQ with 400 mg of soy bean oil (Bio-Quinone(R)); 100 mg of CoQ with 20 mg of polysorbate 80, 100 mg of lecithin and 280 mg of soy bean oil; and 100 mg of CoQ with 20 mg of polysorbate 80 and 380 mg of soy bean oil, respectively. The result suggests that the soy bean oil suspension of CoQ (Bio-Quinone(R)) has the highest bioavailability. A difference in the basic AUC and AUC after p.o. administration of CoQ was observed with respect to sex. A characteristic two-peak pattern was observed at the concentration vs. time profile. ADDITIONAL AUTHORS : Poulsen G; Rasmussen SN
A One Year Bioavailability Study of Coenzyme Q10 with 3Months Withdrawal Period
Folkers K, Moesgaard S, Morita M. Mol Aspects Med 1994 15s s281-s285
Twenty-one healthy subjects received oral Coenzyme Q10 supplementation in soft capsules of 30 mg t.i.d. for 9 months (Bio-Quinone, Pharma Nord, Denmark), followed by a withdrawal period of 3 months. Blood samples were taken before start of supplementation, after 3 and 9 months of supplementation, and finally after 3 months withdrawal. Average blood Coenzyme Q10 concentration increased from about 1 mg/l before supplementation to about 2 mg/l after 3 and 9 months of supplementation, and returned to the pretreatment level after withdrawal. The rise of Coenzyme Q10 concentration was statistically significant (p<0.001, t-test).
Dose dependent effects of coenzyme Q10 on platelet aggregation in swine
Herzog WR, Mortensen SA, Schlossberg ML , Serebruany VL.
J Mol Cell Cardiol 1994 26 LX
ABSTRACT from XV European Section Meeting of ISHR, Denmark, 8-11 June 1994. The effect of dietary supplemented Coenzyme Q10 (CoQ10) on platelet aggregation (PA) in 11 female Yorkshire swine was observed in platelet-rich plasma with 5 mcM ADP. The experimental group received CoQ10 100 mg twice daily (Bio- Qinon, Pharma Nord, Denmark) - group A (n=5);a second group B (n=6), served as controls and received a placebo. Total serum CoQ10 determinations and PA studies were performed at baseline 10 days, and 20 days of CoQ10 or placebo supplementation. PA was determined in the femoral venous blood using a wide blood platelet aggregometer. After 20 days of CoQ10 administration, PA was reduced in a cumulative dose dependent manner as compared to baseline values. Baseline PA was 47.93
Coenzyme Q10 therapy: A metabolic approach which favorably modulates ischemia and thus may prevent failure
Mortensen SA, Crestanello JA, Kamelgard J, Lingle DM, et al.
J Mol Cell Cardiol 1995 27 A396
POSTER SECTION ABSTRACT -XV World Congress of the ISHR, Venice 29 June - 1 July 1995. The use of coenzyme Q10 (CoQ) - an important antioxidant having a key-role in the oxydative phosphorylation - has been promising in heart failure based on the experiences from double-blind multicenter trials. There is increasing evidence from animal experiments that pretreatment with CoQ provides protection for ischemic myocardium. We investigated isolated Langendorff perfused rat hearts pretreated with either CoQ 20 mg/kg i.m. and 10 mg/kg i.p., or vehicle only, 24 and 2 hours prior to 25 min. of ischemia and 40 min. of reperfusion. Dp/dt, MVO2 and aerobic efficiency were measured and 31P NMR spectroscopy was used to determine ATP/PCr concentrations. Hearts were assayed for myocardial CK activity and CoQ content at the end of reperfusion. CoQ pretreatment improved myocardial aerobic efficiency significantly, mediated higher tissue ATP/PCr and protected CK from oxidative inactivation during reperfusion.
Progress on therapy of breast cancer with vitamin Q10 and the regression of metastases.
Lockwood K, Moesgaard S, Yamamoto T, Folkers K.
Biochem Biophys Res Commun 1995 212 172-7
Over 35 years, data and knowledge have internationally evolved from biochemical, biomedical and clinical research on vitamin Q10 (coenzyme Q10; CoQ10) and cancer, which led in 1993 to overt complete regression of the tumors in two cases of breast cancer. Continuing this research, three additional breast cancer patients also underwent a conventional protocol of therapy which included a daily oral dosage of 390 mg of vitamin Q10 (Bio-Quinone of Pharma Nord) during the complete trials over 3-5 years. The numerous metastases in the liver of a 44-year-old patient "disappeared," and no signs of metastases were found elsewhere. A 49-year-old patient, on a dosage of 390 mg of vitamin Q10, revealed no signs of tumor in the pleural cavity after six months, and her condition was excellent. A 75-year-old patient with carcinoma in one breast, after lumpectomy and 390 mg of CoQ10, showed no cancer in the tumor bed or metastases. Control blood levels of CoQ10 of 0.83-0.97 and of 0.62 micrograms/ml increased to 3.34-3.64 and to 3.77 micrograms/ml, respectively, on therapy with CoQ10 for patients A-MRH and EEL.
Q10 og hjertesvikt
Fjelstrup A.Tidsskr Nor L 1995 26 115 3308-10
Summary from sattelite symp. on Q10 held at the congress "Heart Failure 1995" in Amsterdam April 1.- 4. 1995 by The European Society of Cardiology.
Heart failure 1995 - Q10 i focus
1995年心力衰竭 - 辅酶Q10焦点
Fjelstrup A. Ugeskr L 1995 157 45 6281-82
Summary from Sattelite symposium on Q10 in Heart Failure held at the congress "Heart Failure 1995" in Amsterdam, April 1.-4. 1995 by The European Society of Cardiology.
Pharma Nord Satellite Symposium on The Role of Coenzyme Q10 in Ischemia and Heart Failure
Mortensen SA (ed.), Remme WJ (ed.), Sindberg CD
Heart Failure `95, Europ Soc Cardiol 1995
Collection of Abstracts from Pharma Nord Sattelite Symp. at "Heart Failure `95" in Amsterdam April 1.- 4. 1995.
Research in Nutritional Intervention
Sindberg CD. Workshop, Pharma Nord Research, Kolding `95 1995
Abstracts and Proceedings from Pharma Nord Research Konference "Research in Nutritional Intervention" held May 19.-21. 1995 at Hotel Koldingfjord, Kolding, Denmark.
Effects of Peroral Ingestion of Coenzyme Q10 om 31p-MRS detected Skeletal Muscle Energy Metabolism in Post-Polio In.
Mizuno M, Quistorff B, Theorell H, Theorell M, et al.
3. Sci. Meet., Eur. Soc. Magn. Res. Med. Biol. 1995
Abstract presented at the 12. annual meeting; European Society for Magnetic Resonance in Medicine and Biology, Nice, France, Aug. 19. - 25., 1995. Coenzyme Q10 supplementation has demonstrated an improve- ment of oxidative energy metabolism, i.e. a decreased Pi/PCr ratio at rest and during exercise, in mitochondrial myo- pathies. The study evaluated the possibility of the same effect in post-polio patients and healthy controls. 5 subjects vere supplemented for six months with 9o mg CoQ10/day. The post-polio subjects showed a progressive decrease in resting Pi/PCr, less pronounced end-exercise intra- muscular acidosis and faster resynthesis of PCr during recovery.
The roles of coenzyme Q10 and vitamin E on the peroxidationof human low density lipoprotein subfractions.
Alleva R; Tomasetti M, Littarru GP, Folkers K, Battino M ; Curatola G ; et al.
Proc Natl Acad Sci U S A 1995 92 20 9388-91
The aim of our study was to investigate the relationships between the levels of coenzyme Q10 (CoQ10) and vitamin E and the levels of hydroperoxide in three subfractions of low density lipoproteins (LDL) that were isolated from healthy donors. LDL3, the densest of the three subfractions, has shown statistically significant lower levels of CoQ10 and vitamin E, which were associated with higher hydroperoxide levels when compared with the lighter counterparts. After CoQ10 supplementation (Bio-Quinone, Pharma Nord, Denmark), all three LDL subfractions had significantly increased CoQ10 levels. In particular, LDL3 showed the highest CoQ10 increase when compared with LDL1 and LDL2 and was associated with a significant decrease in hydroperoxide level. These results support the hypothesis that the CoQ10 endowment in subfractions of LDL affects their oxidizability, and they have important implications for the treatment of disease. ADDITIONAL AUTHORS :
Effects of Short-Term Supplementation with Coenzyme-Q10 on Myocardial Protection During Cardiac Operations.
Taggart DP, Jenkins M, Hooper J, Hadjinikolas L, et al.
ANN THORAC SURG 1996 61 829-833
Background. Coenzyme Q10 (CoQ10) is a naturally occurring vitamin-like substance that may have a beneficial role in ischemia-reperfusion injury. Coenzyme Q10 administered either as an additive to cardioplegia or as long-term preoperative oral supplementation has been reported to ameliorate myocardial injury after cardiac operations. Methods. To determine whether short-term oral supplementation with large doses of CoQ10 (600 mg in divided doses 12 hours before operation) was effective in myocardial protection, 20 patients with well-preserved left ventricular function (ejection fraction greater than 0.50) undergoing elective coronary revascularization were enrolled in a prospective, double-blind, placebo- controlled, randomized trial. Serial concentrations of CoQ10, myoglobin, creatine kinase MB fraction, and cardiac troponin T were measured preoperatively and 1, 6, 24, 72, and 120 hours postoperatively. Efficacy of myocardial protection was also assessed by clinical outcome and serial changes in electrocardiographic indices. Results. The patient groups were similar with respect to preoperative and intraoperative characteristics. There was no significant difference in the preoperative plasma levels cif CoQ10. These levels fell significantly in both groups after operation, although the magnitude of the decrease was less in the CoQ10-supplemented group (43% versus 60%). In both groups, there were significant postoperative increases in myoglobin, creatine kinase MB fraction, and cardiac troponin T. The magnitude of increases in cardiac troponin T was greater in the CoQ10- supplemented group, reaching marginal overall statistical significance (p = 0.06). Conclusions. Short-term supplementation with large doses of CoQ10 does not lead to improved myocardial protection in patients undergoing coronary revascularization with well-preserved ventricular function and relatively short ischemic times. ADDITIONAL AUTHORS : Kemp M; Hue D; Bennett G
Ubiquinone and total peroxyl radical trapping capacity of LDL lipoproteins during aging: the effects of Q10 suppl.
Alho H, Aejmelaeus R.
9th Intl. Symp. Biomed. and Clin. Aspects of Coenz 1996 20
FULL TITLE : Ubiquinone and total peroxyl radical trapping capacity of LDL lipoproteins during aging: the effects of Q10 supplementation
CoQ10 supplementation and lipoprotein oxidation resistance:a randomized placebo controlled double blind study
Salonen JT, Kaikkonen J, Nyyss, Maijala L, et al.
9th Intl. Symp. Biomed. and Clin. Aspects of Coenz 1996 23
Marathon runners were supplemented with either Bio-Qinon Q10 or placebo for three week before a competition. Level of CoQ10 as well as oxidative resistance in blood lipids was significantly raised before the run. No effect was seen on exercise induced oxidative stress or sparing of other antioxidants. No difference was seen in muscular metabolites or muscular damage. Results suggest that Q10 supplemen- tation might improve oxidative resistance of lipoprotein in sedentary conditions, but does not appear to influence oxidation of LDL or muscular damage due to exhaustive exercise. ADDITIONAL AUTHORS : Porkkala-Sarataho E; Salonen R; Korpela H FULL TITLE : Coenzyme Q10 supplementation and lipoprotein oxidation resistance: a randomized placebo controlled double blind study in marathon runners
Dietary CoQ10 supplementation alters platelet size and inhibits human vitronectin (CD51/CD61) receptor expression
Serebruany VL, Ordonez JV, Herzog WR, Rohde M, et al.
9th Intl. Symp. Biomed. and Clin. Aspects of Coenz 1996 37
Healthy volunteers received 100 mg CoQ10/day for 20 days. Receptor expression and antibodies vere measured. Total serum Q10 increased significantly. Significant inhibition of vitronectin receptor expression was observed in addition to a reduction of platelet size. These findings may not fully be explained by the known antioxidant and bioenergetic properties of CoQ10. The obser- ved changes may contribute to the clinical benefits in patients with cardiovascular diseases. (see also document A-3772) ADDITIONAL AUTHORS : Mortensen SA; Folkers K; Gurbel PA
Progress on therapy of breast cancer with CoQ10 and the regression of metastases
Lockwood K, Moesgaard S, Yamamoto T, Folkers K .
9th Intl. Symp. Biomed. and Clin. Aspects of Coenz 1996 50
Abstract from the 9th International Symposium on Biomedical and Clinical Aspects of Coenzyme Q, Ancona, Italy, 1996.
CoQ10 supplementation does not affect maximal oxygen uptake,31 P-NMR detected metabolism or muscle fatigue in endurance
Mizuno M, Nielsen AN, Ratkevicius A, Mohr T, et al.
9th Intl. Symp. Biomed. and Clin. Aspects of Coenz 1996 80-81
ADDITIONAL AUTHORS : Rohde M; Mortensen SA; Quistorff B FULL TITLE : Coenzyme Q10 supplementation does not affect maximal oxygen uptake, 31P-NMR detected metabolism or muscle fatigue in endurance athletes
ANICA - Adjuvant Nutritional Intervention in Cancer: Current Status (poster)
Poster, 9th Intl. Symp. Biomed. & Clin. Aspects on 1996 1-9
Poster presented at the 9th International Symposium on Biomedical and Clinical Aspects of Coenzyme Q10 in Ancona, Italy, May 16-19,1996.
Effect of CoQ10 on the exercise performance of cross country skiers
Ylikoski T, Penttinen J, Piirainen J
9th Intl. Symp. Biomed. and Clin. Aspects of Coenz 1996 1-8
Poster presented at the 9th International Symposium on Biomedical and Clinical Aspects of Coenzyme Q10 in Ancona, Italy, on May 16-19, 1996. RESULTS: Coenzyme Q10 supplementation was well absorbed and increased the blood levels of Q10 significantly. There was a significant increase in AET, ANT and MaxVO2 after Q10 supplementation compared to placebo. Q10 supplementation of exercise performance, as opposed to placebo supplementation, was not only experienced as having had a clear positive effect; the athletes also noted an improvement in recovery time.
The effects of food supplements (ubiquinone and selenium)on mood and compliance
Alford C, Service J, Hogan J. Conference Paper abstract 1996
The role of health related behaviour based on operant conditioning, whereby behaviour may change as a result of its consequences, can be examined by subjective assessment. The level of non-adherence to recommended lifestyle changes, including diet, may be more than 40% (Sarafino, 1990. Health Psychology, John Wiley) Daily food supplements: ubiquinone 60 mg (Bio-Quinone, Q-10), and a vitamin complex (A, B6, C, E) with zinc (15 mg) and selenium (Bio-Selenium 100 micrograms), were compared to placebo and a no-treatment control in a double-blind, parallel groups design with ten subjects (age range 18-23 years) each assigned to the four groups. Assessments included the Profile of Mood States (POMS); Visual Analogue Scales (VAS) and the UWIST Mood Adjective Checklist (UWAC) completed during baseline and at three and five weeks during treatment. Non-adherence was found in 50% (5/10) of the non-treatment control in comparison to 20% for the placebo and selenium groups, with 100% adherence for the Q10 group. This was partially reflected in mood changes. Significant (P<0.05) increases in energy were reported after five weeks for selenium, as were decreases in tiredness (POMS), increased energy was found for both selenium and Q10 with the VAS measure of energy whilst UWAC indicated similar trends. Results support Benton and Cook's (1990, Pharmacol, 102, 549-550) finding with selenium and suggest improved mood may have a role in compliance to food supplements. (Abstract, Brit Assn for Psychopharmacology, Cambridge, July, 1996)
Effect of Coenzyme Q10 supplementation on platelet aggregability in swine
Herzog WR, Atar D, Mortensen SA, Schlossberg ML, et al. Coenzyme Q 1996 5-8
We studied the effect of dietary supplementation with Coenzyme Ql0 (CoQl0) on platelet aggregation (PA) in 16 female Yorkshire swine. The animal population was divided into 3 groups. The experimental groups received either CoQ10 200 mg twice daily as soft capsules (Bio-Qinon, Pharma Nord, Denmark) (group A, n=5); 100 mg CoQl0 twice daily (group B, n=5); or placebo as an addition to their usual diet (group C, n=6). Three time points for PA studies were chosen: baseline, 10 days and 20 days of CoQl0 or placebo supplementation. PA was induced in venous blood by adding 5
The relation of plasma and CSF antioxidants
Alho HE.Meeting abstract 1994
Abstract of a paper presented at the 77th Biennial Scientific Meeting of the International Society for Free Radical Research in Sydney, Australia, November 6-10, 1994. The relation between the levels of plasma and cerebrospinal fluid (CSF) antioxidants is not well understood. Compared to plasma normal CSF has a low total peroxyl radical trapping parameter (TRAP), uric acid, vitamin-E and ubiquinone (Q-10) but high ascorbic acid content. We studied the effects of oral supplementation of vitamin-C (ASC) and Q-10 on CSF and plasma TRAP and its component concentration in healthy subjects. ASC and Q-10 were administered 500-1000mg and 100-300mg for four weeks respectively. After two weeks of supplementation in plasma both ASC and Q-10 increased significantly (with high dose: ASC from 5l +/- 5 to 75 +/-5.5
Elucidation of a tripartite mechanism underlying the improvement in cardiac tolerance to ischemia by coenzyme Q10
Crestanello JA, Kamelgard J, Lingle DM, Mortensen SA, et al.
J Thorac Cardiovasc Surg 1996 111 443-50
Coenzyme Q10, which is involved in mitochondrial adenosine triphosphate production, is also a powerful antioxidant. We hypothesize that coenzyme Q10 pretreatment protects myocardium from ischemia reperfusion injury both by its ability to increase aerobic energy production and by protecting creatine kinase from oxidative inactivation during reperfusion. Isolated hearts (six per group) from rats pretreated with either coenzyme Q10, 20 mg/kg intramuscularly and 10 mg/kg intraperitoneally (treatment) or vehicle only (control) 24 and 2 hours before the experiment were subjected to 15 minutes of equilibration, 25 minutes of ischemia, and 40 minutes of reperfusion. Developed pressure, contractility, compliance, myocardial oxygen consumption, and myocardial aerobic efficiency were measured. Phosphorus 31 nuclear magnetic resonance (31P-NMR) spectroscopy was used to determine adenosine triphosphate and phosphocreatine concentrations as a percentage of a methylene diphosphonic acid standard. Hearts were assayed for myocardial coenzyme Q10 and myocardial creatine kinase activity at end equilibration and at reperfusion. Treated hearts showed higher myocardial coenzyme Q10 levels (133 +/- 5 micrograms/gm ventricle versus 117 +/- 4 micrograms/gm ventricle, p < 0.05). Developed pressure at end reperfusion was 62% +/- 2% of equilibration in treatment group versus 37% +/- 2% in control group, p < 0.005. Preischemic myocardial aerobic efficiency was preserved during reperfusion in treatment group (0.84 +/- 0.08 mm Hg/(microliter O2/min/gm ventricle) vs 1.00 +/- 0.08 mm Hg/(microliter O2/min/gm ventricle) at equilibration, p = not significant), whereas in the control group it fell to 0.62 +/- 0.07 mm Hg/(microliter O2/min/gm ventricle, p < 0.05 vs equilibration and vs the treatment group at reperfusion. Treated hearts showed higher adenosine triphosphate and phosphocreatine levels during both equilibration (adenosine triphosphate 49% +/- 2% for the treatment group vs 33% +/- 3% in the control group, p < 0.005; phosphocreatine 49% +/- 3% in the treatment group vs 35% +/- 3% in the control group, p < 0.005) and reperfusion (adenosine triphosphate 18% +/- 3% in the treatment group vs 11% +/- 2% in the control group, CTRL p < 0.05; phosphocreatine 45% +/- 2% in the treatment group vs 23% +/- 3% in the control group, p < 0.005). Creatine kinase activity in treated hearts at end reperfusion was 74% +/- 3% of equilibration activity vs 65% +/- 2% in the control group, p < 0.05). Coenzyme Q10 pretreatment improves myocardial function after ischemia and reperfusion. This results from a tripartite effect: (1) higher concentration of adenosine triphosphate and phosphocreatine, initially and during reperfusion, (2) improved myocardial aerobic efficiency during reperfusion, and (3) protection of creatine kinase from oxidative inactivation during reperfusion. ADDITIONAL AUTHORS : Rhode M; Whitman GJ FULL TITLE : Elucidation of a tripartite mechanism underlying the improvement in cardiac tolerance to ischemia by coenzyme Q10 pretreatment.
Wirkung von Antioxidantien unter klinischen Bedingungen
Kuklinski B . Vitaminspur 1994 10 32-35
Oxidative stress is the disbalance between radical generators and radical scavengers in favour of the former. The results of four clinical intervention trials confirm the pathogenic significance of oxidative stress in alcohol-toxic liver disease, myocardial infarction, diabetic late syndrome and acute pancreatitis. A distinct improvement of prognosis could be achieved by using adjuvant antioxidant supplementation (vitamins and trace elements).
Hemostatic changes after dietary coenzyme Q10 supplementation in swine
Serebruany VL, Herzog WR, Atamas SP, Gurbel PA, et al.
J Cardiovasc Pharmacol 1996 28 175-181
Improved cardiovascular morbidity and mortality have been observed in several clinical studies of dietary supplementation with coenzyme Q1O (CoQ1O). We elucidated the effect of CoQ1O on certain hemostatic parameters that may influence the progression of heart disease. Twelve Yorkshire swine were randomized to receive diet supplementation with either CoQ10 or placebo for 20 days. Blood samples were obtained at baseline and at the end of the feeding period. At the end of the protocol, there were no significant differences in hemostatic parameters in the placebo group. A significant increase in total serum CoQ1O level (from 0.39 +/- 0.06 to 0.96
Coenzyme Q10 protects coronary endothelial function from ischemia reperfusion injury via an antioxidant effect
Yokoyama H, Lingle DM, Crestanello JA, Kamelgard J, et al.
Surgery 1996 120 189-196
BACKGROUND. Cardiac ischemia reperfusion (I/R) injury causes coronary vascular dysfunction. Coenzyme Q10 (CoQ), which preserves cardiac mechanical function after I/R, recently has been .recognized as a free radical scavenger. We hypothesized that CoQ protects coronary vascular reactivity after I/R via an antioxidant mechanism. METHODS. Rats were pretreated with either CoQ (20 mg/kg intramuscular and 10 mg/kg intraperitoneal [CoQ group]) or a vehicle (Control) before the experiment. Isolated perfused rat hearts were subjected to 25 minutes of global normothermic ischemia and 40 minutes of reperfusion. The reperfusion-induced oxidative burst was directly assessed by lucigenin enhanced chemiluminescence. Coronary flow was measured at equilibration and after reperfusion with or without bradykinin, an endothelium-dependent vasodilator, and sodium nitroprusside (SNP), an endothelium-independent vasodilator. The effect of intracoronary infusion of hydrogen peroxide (H202 0.1 micro mol/gm body weight given over 5 minutes), simulating the free radical burst after I/R, also was evaluated. RESULTS. I/R decreased the bradykinin-induced change in coronary flow (-5% +/- 4% versus 26 %
A double-blind clinical dose-response study on effects ofCoQ10 on gingival bleeding/periodontal disease in ordinary
Nylander M, Weiner J, Nordlund M
7th Intl Symp on Trends in Biomedicine in Finland 1996 Suppl 8 1-7
Sixty ordinary non smoking Swedish adults were included in this double-blind study. One group of 17 subjects received a daily dose of 30 mg CoQl0 in a soft-gel capsule with CoQl0 emulsified in soybean oil during 10 days. Nineteen subjects received identical capsules with 100 mg CoQlO -in each capsule (Bio-Qinon, Pharma Nord). The remaining 24 subjects were controls and received identical placebo capsules without CoQlO. Gingival bleeding was recorded at the start and at the end of the study. The decrease in gingival bleeding was greatest for the group that was supplemented orally with 100 mg CoQlO per day and least in the placebo group. There was a statistically significant difference in change in gingival bleeding points between the 100 mg CoQlO group and the other two groups (30 mg CoQl0 and placebo); one-tailed T-test p<0.05. FULL TITLE : A double-blind clinical dose-response study on effects of coenzyme Q10 on gingival bleeding/periodontal disease in ordinary people
Dietary CoQ10 supplementation alters platelet size and inhibits human vitronectin (CD51/CD61) receptor expression
Serebruany VL, Ordonez JV, Herzog WR, Rohde M, et al.
J Cardiovasc Pharmacol 1997 29 16-22
Improved cardiovascular morbidity and mortality have been observed in several clinical studies of dietary supplementation with coenzyme Q10 (CoQ10, ubiquinone). Several mechanisms have been proposed to explain the effects of CoQ10, but a comprehensive explanation of its cardioprotective properties is still lacking. One attractive theory links ubiquinone with the inhibition of platelets. The effect of COQ10 intake on platelet size and surface antigens was examined in human volunteers. Study participants received 100 mg of CoQ10 twice daily in addition to their usual diet for 20 days. Receptor expression was measured by flow cytometry with monoclonal murine anti-human antibodies CD9 (p24), CD42B (Ib), CD41b (IIb), CD61 (IIIa), CD41a (IIb/IIIa), CD49b (VLA-2), CD62p (P selectin), CD31 (PECAM- 1), and CD5 I /CD61 (vitronectin). An increase of total serum CoQ10 level (from 0.6
Produktresum Bio-Quinon Q10, MT nr. 6146093
Summary of product characteristics sheet 1997
This document consists of the summary of product characteristics MT no. 6145993 (for Bio-Quinon Q10 30 mg) and MT no. 6146093 (for Bio-Quinon Q10 10 mg) issued by the Danish Medicines Agency on 19 February 1997.
Ubiquinol-10 and total peroxyl radical trapping capacity of LDL lipoproteins during aging: the effects of Q-10
Aejmelaeus R, Mets, Laippala P, Alho H, et al.
Molec Aspects Med 1997 18 Suppl s113-s120
Evidence is rapidly accumulating that oxidative modification of low density lipoprotein (LDL) may play an important role in the pathogenesis of atherosclerosis. In this study we measured the total peroxyl radical trapping capacity of human plasma LDL phospholipids (TRAP-LDL) with a luminescent method. The study was carried out with 70 healthy volunteers, aged 28-77. In males an age-related decrease in TRAP-LDL was observed. In the age group under 50 years, the mean TRAP-LDL was 31.36 +/- 1.45 pmol peroxyl radicals/ nmol Pi; among those over 50 years, it was significantly lower at 26.67 +/- 0.94 pmol/nmol Pi. As regards the components of TRAP-LDL, the concentration of LDL-ubiquinol did not change, and a non-significant decrease in the LDL-tocopherol concentration was detected with age. In females, the mean TRAP-LDL, LDL-ubiquinol-10 and tocopherol concentrations did not differ between the age groups. When 17 of the participants were given coenzyme Ql0 (Ql0) supplementation, 100 mg/day, a highly significant increase in LDL-ubiquinol concentration was detected. Our results indicate that LDL antioxidant defenses tend to decrease with age in the Finnish male population. The decline is most significant in males under 50 years; in older age groups, the values remain stable at a low level. Ql0 supplementation doubles the number of ubiquinol-10-containing LDL molecules and may therefore have an inhibitory effect on LDL oxidation. ADDITIONAL AUTHORS : Solakvi T FULL TITLE : Ubiquinol-10 and total peroxyl radical trapping capacity of LDL lipoproteins during aging: the effects of Q-10 supplementation.
Could coenzyme Q10 affect hemostasis by inhibiting platelet vitronectin (CD51/CD61) receptor?
Serebruany VL, Gurbel PA, Mortensen SA, Folkers K, et al.
Molec Aspects Med 1997 18 Suppl s189-s194
Improved cardiovascular morbidity and mortality have been observed in several clinical studies of dietary supplementation with coenzyme Q10 (CoQ10, ubiquinone). Several mechanisms have been proposed to explain the effects of CoQ10. One attractive theory links ubiquinone with the inhibition of platelets. The effect of CoQ10 intake on platelet surface antigens, and certain hemostatic parameters was examined in 15 humans and 10 swine. Study participants received 100 mg of CoQ10 twice daily in addition to their usual diet for 20 days resulting in a three-fold increase of total serum CoQ10 level. We observed a decline in plasma fibronectin (-20.2%), thromboxane B2 (-20.6%), prostacyclin (-23.2%), and endothelin-1 (-17.9%) level. Significant inhibition of vitronectin receptor expression was observed consistently throughout ubiquinone treatment. Inhibition of the platelet vitronectin receptor is a direct evidence of a link between dietary CoQ10 intake, platelets, and hemostasis. These findings may contribute to the observed clinical benefits by a diminished incidence of thrombotic complications in such patients. ADDITIONAL AUTHORS : Herzog WR; Rohde M; Ordo
The mechanisms of coenzyme Q10 as therapy for myocardialischemia reperfusion injury
Whitman GJR, Nibori K, Crestanello JA, Momeni R, et al.
Molec Aspects Med 1997 18 Suppl s195-s203
It has been hypothesized that CoQ10 (CoQ) pretreatment protects myocardium from ischemia reperfusion (I/R) injury by its ability to increase aerobic energy production as well as its activity as an antioxidant. Isolated hearts from rats pretreated with either CoQ 20 mg/kg i.m. and 10 mg/kg i.p. or vehicle 24 and 2 h prior to the experiment, were subjected to 15 min of equilibration (EQ), 25 min of ischemia, and 40 min of reperfusion (RP). Developed pressure, +/- dp/dt, myocardial oxygen consumption, and myocardial aerobic efficiency (DP/MVO2) were measured. P NMR spectroscopy was used to determine ATP and PCr concentrations. Lucigenin-enhanced chemiluminescence of the coronary sinus effluent was utilized to determine oxidative stress through the protocol. CoQ pretreatment improved myocardial function after ischemia reperfusion. CoQ pretreatment improved tolerance to myocardial ischemia reperfusion injury by its ability to increase aerobic energy production, and by preserving myocardial aerobic efficiency during reperfusion. Furthermore, the oxidative burst during RP was diminished with CoQ. Similarly it was hypothesized that CoQ protected coronary vascular reactivity after I/R via an antioxidant mechanism. Utilizing a newly developed lyposomal CoQ preparation given i.v. 15 min prior to ischemia, ischemia reperfusion was carried out on Langendorff apparatus as previously described. Just prior to ischemia and after RP, hearts were challenged with bradykinin (BK) and sodium nitroprusside (SNP) and change in coronary flow was measured. CoQ pretreatment protected endothelial dependent and endotheliai-independent vasodilation after I/R. We conclude that CoQ pretreatment protects coronary vascular reactivity after I/R via 'OH radical scavenger action. ADDITIONAL AUTHORS : Yokoyama H; Lingle DM
The effect of coenzyme Q10 on sperm motility and function
Lewin A, Lavon H . Molec Aspects Med 1997 18 Suppl s213-s219
In sperm cells, the majority of coenzyme Q10 (CoQ10), an energy promoting agent and antioxidant, is concentrated in the mitochondria of the midpiece, so that the energy for movement and all other energy-dependent processes in the sperm cell also depend on the availability of CoQ10. The reduced form of CoQl0-ubiquinol also acts as an antioxidant, preventing lipid peroxidation in sperm membranes. The objective of the study was to evaluate the effect of CoQ10 on sperm motility in vitro, after incubation with 38 samples of asthenospermic and normal motility sperm, and to evaluate the effect of CoQ10 administration in vivo in 17 patients with low fertilization rates after in vitro fertilization with intracytoplasmic sperm injection (ICSI) for male factor infertility. All 38 sperm samples from patients registered in our infertility clinic had normal concentrations and morphology. Of these, 16 patients had normal motility (mean 47.5%), and 22 patients were asthenospermic (mean motility 19.1%). Sperm samples were divided into four equal parts and incubated for 24 h in: HAM's medium alone, in HAM's medium with 1% DMSO and HAM's with 5 micrograms or 50 micrograms CoQ10. While no significant change in motility after incubation was observed in the samples with initial normal motility, a significant increase in motility was observed in the 50 microgram CoQ10 subgroup of sperm from asthenospermic men, with a motility rate of 35.7 +/- 19.5%, as compared to 19.1 +/- 9.3% in the controls (p< 0.05). The 17 patients with low fertilization rates after ICSI were treated with oral CoQ10, 60 mg/day, for a mean of 103 days before the next ICSI treatment. No significant change was noted in most sperm parameters, but a significant improvement was noted in fertilization rates, from a mean of 10.3 +/- 10.5% in their previous cycles, to 26.3 +/- 22.8% after CoQ10 (p<0.05). In conclusion, the administration of CoQ10 may result in improvement in sperm functions in selective patients. Further investigation into the mechanisms related to these effects is needed.
The effect of coenzyme Q10 on the exercise performance of cross-country skiers
Ylikoski T, Piirainen J, Hanninen O, Penttinen J
Molec Aspects Med 1997 18 Suppl s283-s290
Coenzyme Q10 supplementation (Bio-Qinon Pharma Nord, 90 mg/day) was studied in a double-blind cross-over study of 25 Finnish top-level cross-country skiers. With CoQ10 supplementation, all measured indexes of physical performance (AET, ANT and V02Max) improved significantly. During verum supplementation, 94% of the athletes felt that the preparation had been beneficial in improving their performance and recovery time versus only 33% in the placebo periods.
Mizuno M, Quistorff B, Theorell H, Chance B, et al.
Effects of oral supplementation of coenzyme Q10 on 31P-NMR detected skeletal muscle energy metabolism in middle-aged
Molec Aspects Med 1997 18 Suppl s291-s298
The effects of oral supplementation of 100 mg coenzyme Q10 (CoQ10) for 6 months on muscle energy metabolism during exercise and recovery were evaluated in middle-aged post polio (n = 3) and healthy subjects (n = 4) by the use of phosphorus-31 nuclear magnetic resonance spectroscopy. The metabolic response to isometric plantar flexion at 60% of maximal voluntary contraction force (NWC) for 1.5 min was determined in gastrocnemius muscles before, after 3- (3M0) and 6-month (6M0) of CoQ10 supplementation. The NWC of plantar flexion was unchanged following CoQ10 supplementation. The resting Pi/PCr ratio in gastrocnemius muscles of all subjects decreased after 3MO- and 6MO-CoQ10 (P<0.05). The post-polio individuals showed a progressive decrease in this ratio, while less pronounced changes were observed in the control subjects. Similarly, the post-polio individuals showed a lower Pj/PCr ratio at the end of 60% MVC in both 3MO- and 6MO CoQ10, whereas no change in the ratio was observed in the control subjects. A less pronounced decrease in muscle pH was observed at the end of 60% MVC in both 3MO- and 6MO CoQ10 in the post-polio individuals, but not in the control subjects. No systematic difference in end exercise ATP was observed between the three phases in both groups. The half-time of recovery for PCr decreased in all subjects after 6MO-CoQ10 supplementation (P<0.05). The results suggest that CoQ10 supplementation affects muscle energy metabolism in post-polio individuals to a greater extent than in control subjects. The mechanism for this effect is not clear, but may involve an effect of CoQ10 on peripheral circulation in the calf muscles, its action in mitochondrial oxidative phosphorylation and/or its antioxidant potential. ADDITIONAL AUTHORS : Theorell M FULL TITLE : Effects of oral supplemention of coenzyme Q10 on 31P-NMR detected skeletal muscle energy metabolism in middle-aged post-polio subjects and normal volunteers
The effect of coenzyme Q10 on blood glucose and insulin requirement in patients with insulin dependent diabetes mellitus.
Andersen CB, Henriksen JE, Mortensen SA, Beck-Nielsen H, et al.
Molec Aspects Med 1997 18 Suppl s307-s309
INTRODUCTION: The aim of the study was to investigate the effect of coenzyme Q10 on blood glucose and insulin requirement in patients with insulin dependent diabetes mellitus (IDDM). Several IDDM patients reported independently that they had observed accumulated hypoglycemic episodes and a need for reducing insulin dose after initiating Q10 treatment. Thus, the working hypothesis was that Q10 may have a blood glucose lowering effect and/or an insulin diminishing effect. CONCLUSION: In conclusion, coenzyme Q10 does not improve glycemic control nor diminish the insulin requirement in patients with insulin dependent diabetes mellitus and therefore can be taken freely without risk of hypoglycemic episodes. On the other hand, no beneficial effect on the parameters investigated in our study was observed following Q10 treatment. ADDITIONAL AUTHORS : Hother-Nielsen O; Vaag A FULL TITLE : The effect of coenzyme Q10 on blood glucose and insulin requirement in patients with insulin dependent diabetes mellitus.
Coenzyme Q10 is lower in gingival cervicular fluid inperiodontitis
Lunn R, Rawlinson A, Walsh T, Hodges SJ
Conference Paper, Meeting of Society of Nordic Odo 1997 1-6
Micronutrient concentrations in the periodontal pocket may be important regulators of bacterial growth. A number of the suspected oral pathogens have an absolute requirement for vitamin K, while more benign forms use coenzyme Q10 (Co-Q). There is very little information on gingival crevicular fluid (GCF) levels of micronutrients; indeed, Co-Q has not been measured in this fluid before this study. We collected GCF using Periopaper strips from one diseased site and one healthy site in each of nine patients attending periodontology clinics (age range 27 51, pocket depth 5.9
Antioxidative Therapie in der sekund Myokardinfarktes
Kuklinski B. Journal f 1997 144-51
Sixty-one first-time myocardial infarct patients were randomized for multi-antioxidant therapy or placebo. Patients in the placebo group had a statistically significantly higher risk of developing arrhythmia than patients in the verum group.
Intestinal absorption of coenzyme Q10 administered in a meal or as capsules to healthy subjects
Weber C, Bysted A. Nutrition Research 1997 17 941-945
A randomized cross-over study by supplementation with single doses of coenzyme Q10 (30 mg/person) administered either as a meal consisting of cooked pork heart or as 30 mg coenzyme Ql0 capsules was performed to investigate the bioavailability of dietary coenzyme Ql0 in humans. The increase in serum coenzyme Ql0 concentration was used as an index of the absorption, and reached a maximum six hours after the ingestion of either meal or capsules. Following intake of coenzyme Ql0 capsules, the serum coenzyme Ql0 concentrations increased significantly (p<0.01) from a baseline concentration at 0.88 to 1.19 mg/L. The pork heart meal resulted in a significant (p<0.01) increase in serum coenzyme Ql0 from 0.97 to 1.44 mg/L. The difference between the absorption from meal and capsules was not significant. This study indicates that coenzyme Q10 present in the diet may contribute significantly to plasma coenzyme Q10 concentrations in humans.
Invasive double-blinded placebo-controlled investigation of treatment of congestive heart failure with coenzyme Q10
Munkholm H, Hansen HHT, Rasmussen K
Boston: 1st Conf. of the Intl. Coenzyme Q10 Assn. 1998 67
PURPOSE: To evaluate the effect of coenzyme Q10 (CoQ10) on congestive heart failure. METHOD: 22 patients with left ventricular ejection fraction (LVEF) below 45%, LV internal diameter in diastole of > 60mm And in NYHA class 2-3 received CoQ10 200mg/day or placebo for 3 months. The usual medication was kept unchanged. The groups were comparable regarding all relevant basal parameters. Before and after the treatment period, a right heart catheterisation including a 3 minute exercise test was done. The placebo group showed no significant changes. CONCLUSION: In this setting, CoQ10 200mg/day seemed to improve LV performance in patients suffering from congestive heart failure.
CoQ10: does it have a role in cancer management?
Hodges S, Hertz N, Lister R
Boston: 1st Conf. of the Intl. Coenzyme Q10 Assn. 1998 85
Interaction in absorption and in antioxidative efficiency between coenzyme Q10 and vitamin E in mildly
Kaikkonen J, Nyyss, Tuomainen TP, Salonen JT, et al.
Boston: 1st Conf. of the Intl. Coenzyme Q10 Assn. 1998 98
ADDITIONAL AUTHORS : Porkkala-Sarataho E FULL TITLE : Interaction in absorption and in antioxidative efficiency between coenzyme Q10 and vitamin E in mildly hypercholesterolemic subjects: a placebo-controlled, clinical supplementation study
Reduction of chemotoxicity and enhancement of antioxidant capacity of plasma in cancer patients treated with
Mari D, Alleva R, Tomasetti M, Littarru GP, et al.
Boston: 1st Conf. of the Intl. Coenzyme Q10 Assn. 1998 132-33
ADDITIONAL AUTHORS : Folkers K FULL TITLE : Reduction of chemotoxicity and enhancement of antioxidant capacity of plasma in cancer patients treated with conventional therapy plus CoQ10
A double-blind study on the effect of Coenzyme Q10 on metabolic control in patients with type 2 diabetes mellitus
Eriksson JG, Fors, Mortensen SA, Rohde M
Boston: 1st Conf. of the Intl. Coenzyme Q10 Assn. 1998 158-59
Treatment with CoQ10 was well tolerated among elderly type 2 diabetic patients, and CoQ10 did not interfere with the glycemic control. Thus, CoQ10 may be used in diabetics either prophylactically or as an adjunctive therapy -- especially in association with concomitant diseases like hypertension, coronary heart disease, and heart failure. CoQ10 is without unfavorable effects on the metabolic parameters assessed, and it may have potential benefits under optimal conditions of bioavailability and dosage in type 2 diabetes.
Effect of Q10 on resting energy expenditure in males Q10
Tholle L, Toubro S, Astrup A
International Journal of Obesity 1998 22 （3） (suppl) s158
The Coenzyme Q10 or ubiquinone is widely used as an OT